Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.

Détails

ID Serval
serval:BIB_87F8116B7F24
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Périodique
Molecular Psychiatry
Auteur(s)
Lewczuk P., Kamrowski-Kruck H., Peters O., Heuser I., Jessen F., Popp J., Bürger K., Hampel H., Frölich L., Wolf S., Prinz B., Jahn H., Luckhaus C.h., Perneczky R., Hüll M., Schröder J., Kessler H., Pantel J., Gertz H.J., Klafki H.W., Kölsch H., Reulbach U., Esselmann H., Maler J.M., Bibl M., Kornhuber J., Wiltfang J.
ISSN
1476-5578 (Electronic)
ISSN-L
1359-4184
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
15
Numéro
2
Pages
138-145
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
In this report, we present the results of a multicenter study to test analytic and diagnostic performance of soluble forms of amyloid precursor proteins alpha and beta (sAPP alpha and sAPP beta) in the cerebrospinal fluid (CSF) of patients with different forms of dementing conditions. CSF samples were collected from 188 patients with early dementia (mini-mental state examination >or=20 in majority of cases) and mild cognitive impairment (MCI) in 12 gerontopsychiatric centers, and the clinical diagnoses were supported by neurochemical dementia diagnostic (NDD) tools: CSF amyloid beta peptides, Tau and phospho-Tau. sAPP alpha and sAPP beta were measured with multiplexing method based on electrochemiluminescence. sAPP alpha and sAPP beta CSF concentrations correlated with each other with very high correlation ratio (R=0.96, P<0.001). We observed highly significantly increased sAPP alpha and sAPP beta CSF concentrations in patients with NDD characteristic for Alzheimer's disease (AD) compared to those with NDD negative results. sAPP alpha and sAPP beta highly significantly separated patients with AD, whose diagnosis was supported by NDD findings (sAPP alpha: cutoff, 117.4 ng ml(-1), sensitivity, 68%, specificity, 85%, P<0.001; sAPP beta: cutoff, 181.8 ng ml(-1), sensitivity, 75%, specificity, 85%, P<0.001), from the patients clinically assessed as having other dementias and supported by NDD untypical for AD. We conclude sAPP alpha and sAPP beta might be regarded as novel promising biomarkers supporting the clinical diagnosis of AD.
Mots-clé
Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid, Amyloid beta-Peptides/cerebrospinal fluid, Amyloid beta-Protein Precursor/cerebrospinal fluid, Biological Markers/cerebrospinal fluid, Cognition Disorders/cerebrospinal fluid, Dementia/cerebrospinal fluid, Female, Type="Geographic">Germany, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Sensitivity and Specificity, Statistics as Topic, tau Proteins/cerebrospinal fluid
Pubmed
Open Access
Oui
Création de la notice
20/01/2012 12:22
Dernière modification de la notice
08/05/2019 21:31
Données d'usage